• Home
  • News
  • Portfolio News
  • RevBio Launches an Experiment for its Regenerative Biomaterial on the International Space Station

RevBio Launches an Experiment for its Regenerative Biomaterial on the International Space Station

10Dec

RevBio Launches an Experiment for its Regenerative Biomaterial on the International Space Station

Portfolio News

RevBio, Inc., announced that an experiment to study Tetranite®, the company’s regenerative bone adhesive biomaterial, has successfully been initiated onboard the International Space Station (ISS). Read more >>

Share this post

Related Posts

19Aug

KnipBio appoints business development exec

Russ Heissner will manage feed and aquaculture business relationships Massachusetts bio-tech firm KnipBio has appointed Russ Heissner as senior vice president... read more
25Jun

Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine

Akston Biosciences Corporation and Biolexis, a Strides Group Company, today announced results from a Phase II/III clinical trial in India... read more
26Feb

Aircuity Introduces New Products and Features to Address Commercial Building Health and Wellness Market

Aircuity, the leading global provider of measurably better environments, is excited to announce several new products and additional features to... read more
21Sep

RevBio Receives NIH Grant to Explore the Treatment of Vertebral Compression Fractures with Its Regenerative Bone Adhesive Technology

RevBio, Inc., announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National... read more
12Jan

Student Choice partners with FutureFuel.io to bring highly desired student loan repayment benefits to credit unions

Credit Union Student Choice, the leading provider of higher education financing solutions to America’s credit unions, announced that is has... read more
14Jun

Corbus Pharmaceuticals Presents 1-Year Systemic Sclerosis and 6-Month Dermatomyositis Data from Open-Label Extension of Phase 2 Lenabasum Studies at EULAR 2018

Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to... read more
10Nov

eSight Certified as a Great Place to Work® for Second Year in a Row

Leading vision-enhancement platform, eSight, today announces it has once again been certified as a Great Place to Work® after a... read more
14May

Shiva Kashalkar: Integrating Passion and Business to Create “Netflix” for Toys

When Shiva Kashalkar’s daughter was eight months old, she realized that she was paying several hundred dollars every month for... read more
16Jul

sam® Dramatically Improves the Treatment of Soft Tissue, Arthritis and Joint Issues Without Requiring Surgery or Pain Medication

sam® provides effective and safe treatment of soft tissue, arthritis and joint issues without the need for surgery or pain... read more
02Jul

Carbonite Names Craig Stilwell as Chief Revenue Officer

Carbonite, Inc. (CARB), a global leader in data protection and cybersecurity, today announced the appointment of Craig Stilwell as the... read more